Antibody-drug conjugate （ADC） couplings enable precise tumor targeted chemotherapy by combining cytotoxic drugs with antibodies against tumor cell targetsviaa linker. Trastuzumab emtansine and trastuzumab deruxtecan targeting human epidermal growth factor receptor （HER）2 are effective and have been approved as the standard second-line treatment for HER2-positive metastatic breast cancer. Sacituzumab govitecan targeting trophoblast cell surface antigen-2 has achieved remarkable efficacy in the treatment of metastatic triple-negative breast cancer. Other ADC that targeting Nectin-4， mesothelin， LIV-1， receptor tyrosine kinase-like orphan receptor， HER3， and other targets have reasonable efficacy and broad prospects. Further discussion on the research progress of ADC in the treatment of metastatic breast cancer can provide ideas for the application and development of ADC.